Insmed INSM Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| R&D by Product | ||||||
| ARIKAYCE external R&D expenses | $8.62M-5.3% | $9.1M-1.2% | $9.21M-16.3% | $11M-9.2% | $12.12M-19.6% | |
| Brensocatib external R&D expenses | $18.48M-19.4% | $22.94M+18.5% | $19.36M-42.3% | $33.56M+62.4% | $20.66M-13.8% | |
| Other external R&D expenses | $32.68M-11.1% | $36.76M+0.5% | $36.58M+28.6% | $28.45M+1.3% | $28.08M-20.9% | |
| TPIP external R&D expenses | $37.34M+4.8% | $35.65M+24.0% | $28.75M+39.3% | $20.65M+126% | $9.15M-55.9% | |
| Intangibles, net by Product | ||||||
| AstraZeneca milestone | $43.23M-1.9% | $44.05M+48.2% | $29.73M— | —— | —— | |
| PARI milestones | $911K-5.3% | $962K-5.0% | $1.01M— | —— | —— | |
| Intangible Amortization by Product | ||||||
| AstraZeneca milestone | $818K+21.4% | $674K— | —— | —— | —— | |
| PARI milestones | $51K0.0% | $51K— | —— | —— | —— | |
| Additions by Product | ||||||
| AstraZeneca milestone | $0-100% | $15M— | —— | —— | —— | |
| PARI milestones | $0— | $0— | —— | —— | —— | |
| Product revenues, net by Geography | ||||||
| International | $35.9M-21.8% | $45.88M+13.8% | $40.31M+4.1% | $38.73M+35.7% | $28.55M-22.1% | |
| US | $270.07M+23.9% | $217.96M+114% | $102.04M+48.6% | $68.68M+6.9% | $64.28M-5.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insmed break its business down?
- Insmed (INSM) reports r&d by product across 5 parts — ARIKAYCE external R&D expenses, Brensocatib external R&D expenses, INS1148, Other external R&D expenses and TPIP external R&D expenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Insmed's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insmed's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
